DUBLIN--(BUSINESS WIRE)--The "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. The report analyzes the worldwide markets in US$ Million.
The global and US markets are further analyzed by the following Product Segments:
- Topicals
- Patches
- Others
The report profiles 29 companies including many key and niche players such as:
- AbbVie, Inc. (USA)
- Acerus Pharmaceuticals Corporation (Canada)
- Acrux Limited (Australia)
- Antares Pharma, Inc. (USA)
- Bayer HealthCare Pharmaceuticals (Germany)
- Eli Lilly and Company (USA)
- Endo Pharmaceuticals Inc. (USA)
- Kyowa Kirin (UK)
Key Topics Covered
1. Industry Overview
2. Growth Drivers and Market Trends
- Aging Global Population Drives Adoption
- Undiagnosed Patients - A Strong Indicator of Growth Potential
- Rising Awareness - A Critical Factor for Growth
- Untapped Developing Markets - The Future Growth Engine for TRT
- Emerging Data on Positive Impact on Co-morbidities to Support Growth
- Debunking Conventional Wisdom, New Studies Dissociate Prostate Cancer Risk with TRT
- Marketing Campaigns and Patient Referrals to Fuel Growth
- Easy-to-use Formulations - A Major Boost to TRT Market
- Testosterone as Treatment for Other Conditions - A Growing Area of Focus
3. Competition
4. Testosterone Deficiency and TRT
5. Product Launches/Approvals
6. Recent Industry Activity
7. Focus on Select Players
8. Global Market Perspective
Total Companies Profiled: 29 (including Divisions/Subsidiaries 31)
- The United States (17)
- Canada (2)
- Japan (2)
-
Europe (7)
- Germany (1)
- The United Kingdom (4)
- Rest of Europe (2)
- Asia-Pacific (Excluding Japan) (3)
For more information about this report visit https://www.researchandmarkets.com/research/6vvlwq/global_strategic?w=4
